AORT vs ENOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

AORT

38.7
AI Score
VS
AORT Wins

ENOV

29.5
AI Score

Investment Advisor Scores

AORT

39score
Recommendation
AVOID NEW MONEY

ENOV

30score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric AORT ENOV Winner
Forward P/E 30.3951 6.9109 ENOV
PEG Ratio 181.5 1.8989 ENOV
Revenue Growth 9.2% 1.8% AORT
Earnings Growth 0.0% 153.1% ENOV
Tradestie Score 38.7/100 29.5/100 AORT
Profit Margin -3.6% -22.9% AORT
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY AVOID NEW MONEY Tie

Relative Price Performance (Last 90 Days)

AORT 1M: -6.1% · 3M: -28.5% ENOV 1M: +54.6% · 3M: +14.3%

Current Technical Phase

AORT

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.5%), weak momentum, RSI 40

RSI (14): 39.5 · Price: $20.47

ENOV

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 70

RSI (14): 70.2 · Price: $28.22

Fundamentals Snapshot

Metric AORT ENOV
Market Cap — —
Forward P/E 39.4 8.1
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.1% 0.0%
Gross Margin 0.6% 0.6%
Operating Margin 0.0% 0.0%
EPS -0.36 -9.23
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, AORT is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.